- Product Sales of $6.4 billion -
- Diluted EPS of $2.05 per share -
- Non-GAAP Diluted EPS of $2.23 per share
-
- Reiterates Full Year 2017 Guidance
-
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results
of operations for the first quarter ended March 31, 2017. The
financial results that follow represent a year-over-year comparison
of the first quarter 2017 to the first quarter 2016. Total revenues
were $6.5 billion in 2017 compared to $7.8 billion in 2016. Net
income was $2.7 billion or $2.05 per diluted share in 2017 compared
to $3.6 billion or $2.53 per diluted share in 2016. Non-GAAP net
income, which excludes amounts related to acquisition-related,
up-front collaboration, stock-based compensation and other
expenses, was $2.9 billion or $2.23 per diluted share in 2017
compared to $4.3 billion or $3.03 per diluted share in 2016.
Three Months Ended March 31, (In millions,
except per share amounts) 2017 2016
Product sales $ 6,377 $ 7,681 Royalty, contract and other revenues
128 113
Total revenues
$ 6,505 $ 7,794 Net income attributable to Gilead $
2,702 $ 3,566 Non-GAAP net income* $ 2,949 $ 4,274 Diluted
earnings per share $ 2.05 $ 2.53
Non-GAAP diluted earnings per share*
$ 2.23 $ 3.03
* Non-GAAP net income and non-GAAP diluted earnings per share
exclude acquisition-related, up-front collaboration, stock-based
compensation and other expenses. A reconciliation between GAAP and
non-GAAP financial information is provided in the tables on pages 7
and 8.
Product Sales
Total product sales for the first quarter of 2017 were $6.4
billion compared to $7.7 billion for the same period in 2016.
Product sales for the first quarter of 2017 were $4.5 billion in
the United States, $1.3 billion in Europe and $661 million in other
locations. Product sales for the first quarter of 2016 were $4.4
billion in the United States, $1.6 billion in Europe and $1.7
billion in other locations.
Antiviral Product Sales
Antiviral product sales, which include sales of our HIV, chronic
hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8
billion for the first quarter of 2017 compared to $7.2 billion for
the same period in 2016.
- HIV and HBV product sales were $3.3
billion compared to $2.9 billion for the same period in 2016. The
increase was primarily due to the continued uptake of our tenofovir
alafenamide (TAF) based products, Genvoya® (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10
mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg)
and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir
alafenamide 25 mg).
- HCV product sales, which consist of
Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir
400 mg) and Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), were
$2.6 billion compared to $4.3 billion for the same period in 2016.
The decline was due to lower sales of Harvoni and Sovaldi across
all major markets, partially offset by sales of Epclusa, which was
launched in the United States and Europe in June and July 2016,
respectively.
Other Product Sales
Other product sales, which include Letairis® (ambrisentan),
Ranexa® (ranolazine) and AmBisome® (amphotericin B liposome for
injection), were $536 million for the first quarter of 2017
compared to $498 million for the same period in 2016.
Operating Expenses
Three Months Ended March 31, (In
millions) 2017 2016 Research and
development expenses (R&D) $ 931 $ 1,265 Non-GAAP R&D
expenses* $ 889 $ 769 Selling, general and administrative
expenses (SG&A) $ 850 $ 685 Non-GAAP SG&A expenses* $ 807 $
638
* Non-GAAP R&D and SG&A expenses exclude
acquisition-related, up-front collaboration, stock-based
compensation and other expenses. A reconciliation between GAAP and
non-GAAP financial information is provided in the tables on pages 7
and 8.
During the first quarter of 2017, compared to the same period in
2016:
- R&D expenses decreased primarily
due to the 2016 impact of up-front collaboration expenses related
to Gilead’s license and collaboration agreement with Galapagos NV
and impairment charges related to in-process R&D. These
decreases were partially offset by expenses associated with
Gilead’s purchase of a U.S. Food and Drug Administration (FDA)
priority review voucher.
- Non-GAAP R&D expenses* increased
primarily due to expenses associated with Gilead’s purchase of an
FDA priority review voucher.
- SG&A expenses and non-GAAP SG&A
expenses* increased primarily due to higher branded prescription
drug fee expense.
Cash, Cash Equivalents and Marketable
Securities
As of March 31, 2017, Gilead had $34.0 billion of cash, cash
equivalents and marketable securities compared to $32.4 billion as
of December 31, 2016. Cash flow from operating activities was $2.9
billion for the quarter. During the first quarter of 2017, Gilead
utilized $565 million on stock repurchases and paid cash dividends
of $687 million.
Full Year 2017 Guidance
Reiterated
Gilead reiterates its full year 2017 guidance, initially
provided on February 7, 2017:
(In millions, except percentages and per share amounts)
Initially Provided
February 7, 2017
Net Product Sales $22,500 - $24,500 Non-HCV Product Sales $15,000 -
$15,500 HCV Product Sales $7,500 - $9,000 Non-GAAP* Product Gross
Margin 86% - 88% R&D Expenses $3,100 - $3,400 SG&A Expenses
$3,100 - $3,400 Effective Tax Rate 25.0% - 28.0% Diluted EPS Impact
of Acquisition-related, Up-front Collaboration, Stock-based
Compensation and Other Expenses $0.84 - $0.91
* Non-GAAP Product Gross Margin, R&D and SG&A expenses
and effective tax rate exclude acquisition-related, up-front
collaboration, stock-based compensation and other expenses. A
reconciliation between GAAP and non-GAAP full year 2017 guidance is
provided in the tables on page 9.
Corporate Highlights
- Announced that Alessandro Riva, MD,
joined the company as Senior Vice President and therapeutic area
head for hematology and oncology.
- Announced the recipients of Gilead’s
HIV cure grants program, a fund totaling more than $22 million,
which will support 12 new HIV cure research projects. These
projects will be conducted by leading academic institutions,
non-profit organizations and community groups from around the
world, focusing on three key areas: translational research,
efficacy studies in animal models and community perspectives of HIV
cure.
Product and Pipeline Updates announced
by Gilead during the First Quarter of 2017 include:
Antiviral and Liver Diseases Programs
- Presented data at the 2017 Conference
on Retroviruses and Opportunistic Infections which included the
announcement of:
- Positive results from a Phase 2 study
evaluating the efficacy, safety and tolerability of a combination
of bictegravir (75 mg) (BIC) and emtricitabine/tenofovir
alafenamide (200/25 mg) (FTC/TAF) versus dolutegravir (50 mg) (DTG)
and FTC/TAF in treatment-naïve, HIV-1 infected adults. Results
found that the BIC+FTC/TAF and DTG+FTC/TAF regimens both
demonstrated high virologic response rates at week 24 and week
48.
- Positive findings from a preclinical
study evaluating HIV capsid inhibitors (CAIs) for potential use as
a long-acting antiretroviral (ARV) treatment. The study identified
novel HIV-1 CAIs with highly potent antiviral activity and a
favorable resistance profile to existing ARVs in vitro.
- Positive 144-week data from two Phase 3
studies (Studies 104 and 111) evaluating the safety and efficacy of
Genvoya for the treatment of HIV-1 infection in treatment-naïve
adults. Through week 144, Genvoya demonstrated significantly higher
rates of virologic suppression compared to Stribild® (elvitegravir
150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir
disoproxil fumarate 300 mg), based on the percentage of patients
with HIV-1 RNA levels less than 50 copies/mL. Patients receiving
Genvoya also demonstrated favorable renal and bone laboratory
parameters compared to those treated with Stribild.
- Announced that the marketing
authorization application for the investigational, once-daily,
single-tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and
voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of HCV-infected
patients has been fully validated and is under assessment by the
European Medicines Agency. Gilead also previously submitted a new
drug application to FDA for SOF/VEL/VOX. Under the Prescription
Drug User Fee Act, FDA has set a target action date of August 8,
2017.
- Announced that the European Commission
granted marketing authorization for Vemlidy® (tenofovir alafenamide
25mg), a once-daily tablet for the treatment of chronic hepatitis B
virus infection in adults and adolescents (aged 12 years and older
with body weight at least 35 kg).
Non-GAAP Financial
Information
The information presented in this document has been prepared by
Gilead in accordance with U.S. generally accepted accounting
principles (GAAP), unless otherwise noted as non-GAAP. Management
believes non-GAAP information is useful for investors, when
considered in conjunction with Gilead’s GAAP financial information,
because management uses such information internally for its
operating, budgeting and financial planning purposes. Non-GAAP
information is not prepared under a comprehensive set of accounting
rules and should only be used to supplement an understanding of
Gilead’s operating results as reported under GAAP. Non-GAAP
measures may be defined and calculated differently by other
companies in the same industry. A reconciliation between GAAP and
non-GAAP financial information is provided in the tables on pages
7, 8 and 9.
Conference Call
At 4:30 p.m. Eastern Time today, Gilead’s management will host a
conference call and a simultaneous webcast to discuss results from
its first quarter 2017 and a general business update. To access the
webcast live via the internet, please connect to the company’s
website at www.gilead.com/investors 15
minutes prior to the conference call to ensure adequate time for
any software download that may be needed to hear the webcast.
Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393
(international) and dial the conference ID 91219047 to access the
call.
A replay of the webcast will be archived on the company’s
website for one year, and a phone replay will be available
approximately two hours following the call through May 4, 2017. To
access the phone replay, please call 1-855-859-2056 (U.S.) or
1-404-537-3406 (international) and dial the conference ID
91219047.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
Forward-looking
Statements
Statements included in this press release that are not
historical in nature are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Gilead cautions readers that forward-looking statements are subject
to certain risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include:
Gilead’s ability to achieve its anticipated full year 2017
financial results; Gilead’s ability to sustain growth in revenues
for its antiviral and other programs; the risk that estimates of
patients with HCV or anticipated patient demand may not be
accurate; the risk that private and public payers may be reluctant
to provide, or continue to provide, coverage or reimbursement for
new products, including Vemlidy, Epclusa, Descovy, Odefsey and
Genvoya; the potential for increased pricing pressure globally and
contracting pressure as well as decreased volume and market share
from additional competitive HCV launches; a larger than anticipated
shift in payer mix to more highly discounted payer segments and
geographic regions and decreases in treatment duration;
availability of funding for state AIDS Drug Assistance Programs
(ADAPs) and Veterans Administration (VA); continued fluctuations in
ADAP and VA purchases driven by federal and state grant cycles
which may not mirror patient demand and may cause fluctuations in
Gilead’s earnings; market share and price erosion caused by the
introduction of generic versions of Viread and Truvada outside the
United States; potential amendments to the Affordable Care Act or
other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility
of unfavorable results from clinical trials involving
investigational compounds; the levels of inventory held by
wholesalers and retailers which may cause fluctuations in Gilead’s
earnings; Gilead’s ability to submit new drug applications and
receive regulatory approval for new product candidates in the
timelines currently anticipated or at all; Gilead’s ability to
successfully develop its oncology, inflammation, cardiovascular and
respiratory programs; safety and efficacy data from clinical
studies may not warrant further development of Gilead’s product
candidates, including BIC+FTC/TAF and certain HIV CAIs; Gilead’s
ability to pay dividends or complete its share repurchase program
due to changes in its stock price, corporate or other market
conditions; fluctuations in the foreign exchange rate of the U.S.
dollar that may cause an unfavorable foreign currency exchange
impact on Gilead’s future revenues and pre-tax earnings; and other
risks identified from time to time in Gilead’s reports filed with
the U.S. Securities and Exchange Commission (SEC). In addition,
Gilead makes estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and related
disclosures. Actual results may differ significantly from these
estimates. You are urged to consider statements that include the
words may, will, would, could, should, might, believes, estimates,
projects, potential, expects, plans, anticipates, intends,
continues, forecast, designed, goal, or the negative of those words
or other comparable words to be uncertain and forward-looking.
Gilead directs readers to its press releases, Annual Report on Form
10-K for the year ended December 31, 2016 and other subsequent
disclosure documents filed with the SEC. Gilead claims the
protection of the Safe Harbor contained in the Private Securities
Litigation Reform Act of 1995 for forward-looking statements.
All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Gilead owns or has rights to various
trademarks, copyrights and trade names used in our business,
including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®,
CAYSTON®, COMPLERA®, DESCOVY®, EMTRIVA®, EPCLUSA®, EVIPLERA®,
GENVOYA®, HARVONI®, HEPSERA®, LETAIRIS®, ODEFSEY®, RANEXA®,
SOVALDI®, STRIBILD®, TRUVADA®, TYBOST®, VEMLIDY®, VIREAD®,
VITEKTA®, VOLIBRIS®, and ZYDELIG®.
ATRIPLA® is a registered trademark of Bristol-Myers
Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered
trademark of Astellas U.S. LLC. MACUGEN® is a registered trademark
of Eyetech, Inc. SUSTIVA® is a registered trademark of
Bristol-Myers Squibb Pharma Company. TAMIFLU® is a registered
trademark of Hoffmann-La Roche Inc.
For more information on Gilead Sciences, Inc.,
please visit www.gilead.com or call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235).
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME
(unaudited)
(in millions, except per share
amounts)
Three Months Ended March 31, 2017
2016 Revenues: Product sales $ 6,377 $ 7,681 Royalty,
contract and other revenues 128 113 Total revenues
6,505 7,794 Costs and expenses: Cost of goods sold
957 1,193 Research and development expenses 931 1,265 Selling,
general and administrative expenses 850 685 Total
costs and expenses 2,738 3,143 Income from operations
3,767 4,651 Interest expense (261 ) (230 ) Other income (expense),
net 111 81 Income before provision for income taxes
3,617 4,502 Provision for income taxes 918 935 Net
income 2,699 3,567 Net income (loss) attributable to noncontrolling
interest (3 ) 1 Net income attributable to Gilead $ 2,702
$ 3,566 Net income per share attributable to
Gilead common stockholders - basic $ 2.07 $ 2.58 Shares used in per
share calculation - basic 1,308 1,383 Net income per share
attributable to Gilead common stockholders - diluted $ 2.05 $ 2.53
Shares used in per share calculation - diluted 1,320 1,412 Cash
dividends declared per share $ 0.52 $ 0.43
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended March 31, 2017
2016 Cost of goods sold reconciliation: GAAP
cost of goods sold $ 957 $ 1,193 Acquisition related-amortization
of purchased intangibles (210 ) (210 ) Stock-based compensation
expenses (4 ) (3 ) Other(1) — 3 Non-GAAP cost of
goods sold $ 743 $ 983
Product gross margin
reconciliation: GAAP product gross margin 85.0 % 84.5
%
Acquisition related-amortization of purchased intangibles 3.3 % 2.7
%
Non-GAAP product gross margin(2) 88.3 % 87.2
%
Research and development expenses reconciliation:
GAAP research and development expenses $ 931 $ 1,265 Up-front
collaboration expenses — (368 ) Acquisition related-IPR&D
impairment — (114 ) Stock-based compensation expenses (42 ) (41 )
Other(1) — 27 Non-GAAP research and development
expenses $ 889 $ 769
Selling, general and
administrative expenses reconciliation: GAAP selling, general
and administrative expenses $ 850 $ 685 Stock-based compensation
expenses (43 ) (44 ) Other(1) — (3 ) Non-GAAP selling,
general and administrative expenses $ 807 $ 638
Operating margin reconciliation: GAAP operating
margin 57.9 % 59.7
%
Up-front collaboration expenses — % 4.7
%
Acquisition related-amortization of purchased intangibles 3.2 % 2.7
%
Acquisition related-IPR&D impairment — % 1.5
%
Stock-based compensation expenses 1.4 % 1.1
%
Other(1) — % (0.3 )% Non-GAAP operating margin(2) 62.5 % 69.3
%
Notes: (1) Amounts related to contingent consideration,
consolidation of a contract manufacturer and/or other individually
insignificant amounts (2) Amounts may not sum due to rounding
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION - (Continued)
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended March 31, 2017
2016 Effective tax rate reconciliation: GAAP
effective tax rate 25.4
%
20.8
%
Up-front collaboration expenses —
%
(1.5 )% Acquisition related-amortization of purchased intangibles
(1.2 )% (0.7 )% Stock-based compensation expenses(1) 0.6
%
—
%
Other(2) —
%
0.1
%
Non-GAAP effective tax rate(3) 24.8
%
18.7
%
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead $ 2,702 $ 3,566 Up-front
collaboration expenses — 368 Acquisition related-amortization of
purchased intangibles 202 204 Acquisition related-IPR&D
impairment — 99 Stock-based compensation expenses(1) 45 64 Other(2)
— (27 ) Non-GAAP net income attributable to Gilead $ 2,949
$ 4,274
Diluted earnings per share
reconciliation: GAAP diluted earnings per share $ 2.05 $ 2.53
Up-front collaboration expenses — 0.26 Acquisition
related-amortization of purchased intangibles 0.15 0.14 Acquisition
related-IPR&D impairment — 0.07 Stock-based compensation
expenses(1) 0.03 0.05 Other(2) — (0.02 ) Non-GAAP diluted
earnings per share(3) $ 2.23 $ 3.03
Non-GAAP adjustment summary: Cost of goods sold adjustments
$ 214 $ 210 Research and development expenses adjustments 42 496
Selling, general and administrative expenses adjustments 43
47 Total non-GAAP adjustments before tax 299 753 Income tax
effect(1) (52 ) (45 ) Total non-GAAP adjustments after tax $ 247
$ 708 Notes: (1) Income tax effect related to
stock-based compensation expenses for the three months ended March
31, 2017 include the incremental tax benefit of $20 million
recognized from the adoption of Accounting Standards Update 2016-09
“Improvements to Employee Share-Based Payment Accounting” (2)
Amounts related to contingent consideration, consolidation of a
contract manufacturer and/or other individually insignificant
amounts (3) Amounts may not sum due to rounding
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP 2017
FULL YEAR GUIDANCE
(unaudited)
(in millions, except percentages and
per share amounts)
Initially Provided
February 7, 2017
Reiterated
May 2, 2017
Projected product gross margin GAAP to non-GAAP
reconciliation: GAAP projected product gross margin 82% - 84%
Acquisition-related expenses 4% - 4% Non-GAAP projected product
gross margin(1) 86% - 88%
Projected research and
development expenses GAAP to non-GAAP reconciliation: GAAP
projected research and development expenses $3,295 - $3,640
Acquisition-related expenses / up-front collaboration expenses (15)
- (45) Stock-based compensation expenses (180) - (195) Non-GAAP
projected research and development expenses $3,100 - $3,400
Projected selling, general and administrative expenses GAAP to
non-GAAP reconciliation: GAAP projected selling, general and
administrative expenses $3,305 - $3,615 Stock-based compensation
expenses (205) - (215) Non-GAAP projected selling, general and
administrative expenses $3,100 - $3,400
Projected diluted
EPS impact of acquisition-related, up-front collaboration,
stock-based compensation and other expenses:
Acquisition-related expenses / up-front collaboration expenses
$0.62 - $0.67 Stock-based compensation expenses 0.22 - 0.24
Projected diluted EPS impact of acquisition-related, up-front
collaboration, stock-based compensation and other expenses $0.84 -
$0.91 Note: (1) Stock-based compensation expenses have a
less than one percent impact on non-GAAP projected product gross
margin
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited)
(in millions)
March 31, December 31, 2017
2016(1) Cash, cash equivalents and marketable
securities $ 34,017 $ 32,380 Accounts receivable, net 4,034 4,514
Inventories 1,474 1,587 Property, plant and equipment, net 2,922
2,865 Intangible assets, net 8,761 8,971 Goodwill 1,172 1,172 Other
assets 5,321 5,488 Total assets $ 57,701 $ 56,977
Current liabilities $ 8,282 $ 9,218 Long-term liabilities
28,502 28,396 Stockholders’ equity(2) 20,917 19,363 Total
liabilities and stockholders’ equity $ 57,701 $ 56,977
Notes: (1) Derived from the audited consolidated financial
statements as of December 31, 2016. Certain amounts have been
reclassified to conform to current year presentation (2) As of
March 31, 2017, there were 1,307 million shares of common stock
issued and outstanding
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in millions)
Three Months Ended March 31, 2017
2016 Antiviral products: Harvoni – U.S. $ 926 $ 1,407
Harvoni – Europe 243 555 Harvoni – Other International 202
1,055 1,371 3,017 Epclusa – U.S. 735 — Epclusa –
Europe 138 — Epclusa – Other International 19 — 892 —
Genvoya – U.S. 669 141 Genvoya – Europe 87 16 Genvoya –
Other International 13 1 769 158 Truvada –
U.S. 464 576 Truvada – Europe 189 251 Truvada – Other International
61 71 714 898 Atripla – U.S. 316 489 Atripla –
Europe 94 143 Atripla – Other International 42 43 452
675 Sovaldi – U.S. 27 645 Sovaldi – Europe 106 280 Sovaldi –
Other International 180 352 313 1,277 Stribild
– U.S. 226 376 Stribild – Europe 67 81 Stribild – Other
International 16 20 309 477 Viread – U.S. 117
123 Viread – Europe 71 76 Viread – Other International 72 73
260 272 Complera / Eviplera – U.S. 112 222 Complera /
Eviplera – Europe 125 146 Complera / Eviplera – Other International
16 13 253 381 Descovy – U.S. 209 — Descovy –
Europe 37 — Descovy – Other International 5 — 251 —
Odefsey – U.S. 203 11 Odefsey – Europe 23 — Odefsey – Other
International 1 — 227 11
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY -
(Continued)
(unaudited)
(in millions)
Three Months Ended March 31, 2017
2016 Other Antiviral – U.S. $ 25 $ 10 Other
Antiviral – Europe 4 6 Other Antiviral – Other International 1
1 30 17 Total antiviral products – U.S. 4,029
4,000 Total antiviral products – Europe 1,184 1,554 Total antiviral
products – Other International 628 1,629 5,841 7,183
Other products: Letairis 211 175 Ranexa 153 144 AmBisome 92
86 Zydelig 35 49 Other 45 44 536 498 Total
product sales $ 6,377 $ 7,681
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170502006582/en/
Gilead Sciences, Inc.InvestorsRobin Washington, 650-522-5688Sung
Lee, 650-524-7792MediaAmy
Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024